<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01704612</url>
  </required_header>
  <id_info>
    <org_study_id>2011-PC001</org_study_id>
    <nct_id>NCT01704612</nct_id>
  </id_info>
  <brief_title>Evaluation of Block Duration in Type 2 Diabetes Patients</brief_title>
  <acronym>Diabeteblock</acronym>
  <official_title>Comparison of Subgluteal Sciatic Nerve Block Duration in Type-2 Diabetic and Non Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre and Marie Curie University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pierre and Marie Curie University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabete animal studies demonstrated a longer period recovery after local anesthetic injection
      (perineural administration). No clinical study demonstrated a prolonged nerve block duration
      in diabete type 2 patients after peripheral nerve block. The investigators hypothesized that
      block recovery is delayed in diabetic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For diabetic patients, peripheral nerve block is an interesting alternative to general
      anesthesia because it provides effective analgesia and may decrease haemodynamic
      complication. The fear of nerve injury after regional anaesthesia in diabetic patients is a
      concern that has neither been confirmed nor refuted by current literature. As a matter of
      fact, diabetic patients with neuropathy may be considered at increased risk because of the
      possibility for double crush syndrome when a chronic axon lesion related to diabetes is
      associated with an unexpected distal nerve injury related to regional anaesthesia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the duration of sensory block in hours</measure>
    <time_frame>Day 0</time_frame>
    <description>The beginning of this term is defined by the end of the sciatic block injection, and the end of this period is defined by the reappearance of sensitivity to pin-prick test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the duration of motor sciatic block</measure>
    <time_frame>Day 0</time_frame>
    <description>The beginning of this term is defined by the end of the sciatic block injection, and the end of this period is defined by the reappearance of motor function</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time necessary for onset sensory and motor block time in minutes</measure>
    <time_frame>Day 0</time_frame>
    <description>peroperative period</description>
  </other_outcome>
  <other_outcome>
    <measure>Failure of the block: yes/no</measure>
    <time_frame>Day 0</time_frame>
    <description>perop</description>
  </other_outcome>
  <other_outcome>
    <measure>occurrence of neurological omplications, yes/no</measure>
    <time_frame>1 month</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Diabetes Type 2</condition>
  <arm_group>
    <arm_group_label>Diabete group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient with type 2 diabete received 20 mL ropivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>no diabete reveived 20 mL ropivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ropivacaine</intervention_name>
    <description>patients received 20 mL ropivacaine 5 mg/mL on subgluteal nerve</description>
    <arm_group_label>Diabete group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>naropin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age (50 80 yrs) with monofilament test 10 g (&gt; 4/8)

        Exclusion Criteria:

          -  refusal of sciatic nerve block,

          -  age &lt; 50 yr or &gt; 80 yr,

          -  American Society of Anesthesiologists state &gt; IV,

          -  presence of contraindications to local anaesthesia (known allergy to local
             anaesthetics, sepsis),

          -  emergency surgery,

          -  patients unlikely to be fully cooperative during the study,

          -  psychiatric disorders, or

          -  those abusing alcohol or drugs, and

          -  participation in another study within the previous 30 days. Moreover, patients with
             preoperative estimated values of creatinine clearance &lt; 50 mL min-1 (Cockroft and
             Gault Formula) or with glycosylated hemoglobin (A1c) level &gt; 8 % or with type 1
             diabetes mellitus (insulin therapy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Cuvillon, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP Pitié Salpetriere</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>APHP Pitié-Sampetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2012</study_first_submitted>
  <study_first_submitted_qc>October 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2012</study_first_posted>
  <last_update_submitted>December 21, 2012</last_update_submitted>
  <last_update_submitted_qc>December 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire de Nīmes</investigator_affiliation>
    <investigator_full_name>Philippe Cuvillon</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>local anesthetic</keyword>
  <keyword>sciatic</keyword>
  <keyword>diabetes</keyword>
  <keyword>block</keyword>
  <keyword>duration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

